Differentiating Hepatic Metastases Of Gastroenteropancreatic Neuroendocrine Cancer And Adenocarcinoma Using Enhanced Ct

Yong Cui,Xiao-Ting Li,Jie Li,Zhong-Wu Li,Yan-Jie Shi,Hui-Ci Zhu,Ying-Shi Sun

2018-01-01

Abstract:Recent studies have demonstrated that dynamic enhanced CT has potential for distinguishing gastroenteropancreatic neuroendocrine cancer (GEP-NEC) from gastroenteropancreatic adenocarcinoma (GEP-ADC). However, little is known about the performance of CT in differentiating hepatic metastases of those tumors. We therefore aimed to assess the capability of contrast-enhanced CT to differentiate between GEP-NEC and GEP-ADC hepatic metastases. CT images of 33 cases of GEP-NEC hepatic metastases and 33 cases of GEP-ADC hepatic metastases were retrospectively reviewed. Qualitative analysis included tumor distribution, the presence or absence of tumor-feeding arteries and intratumoral neovascularity, and dynamic enhancement patterns. Quantitative analysis included tumor size, tumor number, measurement of CT attenuation of tumors and adjacent liver parenchyma, and calculation of the enhancement ratio of the lesion versus the surrounding liver in the hepatic arterial phase (T-L/A) and portal venous phase. There was a significantly higher prevalence of tumor feeding arteries (72.7% vs. 36.4%, p=0.003) and intratumoral neovascularity (57.6% vs. 12.1%, p<0.001) and less plateau enhancement (42.4% vs. 84.8%, p=0.002) in GEP-NEC hepatic metastases than GEP-ADC hepatic metastases. The mean T-L/A in GEP-NEC hepatic metastases was significantly higher compared to GEP-ADC hepatic metastases (0.90 +/- 0.24 vs. 0.72 +/- 0.19, p=0.001). Regression analysis identified the presence of intratumoral neovascularity as the only independent predictor of GEP-NEC hepatic metastases on CT (odds ratio=7.097; 95% CI=1.852-27.196; p=0.004). Together, these results suggest that contrast-enhanced CT may have clinical application in the differential diagnosis of hepatic metastases from GEP-NEC or GEP-ADC.